Daiichi Sankyo ( Daiichi Sankyo )

Daiichi Sankyo

Daiichi Sankyo's picture

About Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Daiichi Sankyo press release, blog etc

10/31/2018 - 05:22 Daiichi Sankyo Announces Discontinuation of Intradermal Seasonal Influenza Vaccine Development in Japan
10/31/2018 - 04:48 Announcement for partnership termination of sales and information provision of lyophilized hemophilus influenza type b vaccine ActHIB in Japan
10/18/2018 - 16:28 Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
10/17/2018 - 05:38 Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
10/09/2018 - 00:22 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
10/02/2018 - 22:33 Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
09/11/2018 - 18:19 Daiichi Sankyos FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML
08/07/2018 - 06:11 Daiichi Sankyo Announces Change in Principal Shareholders
08/01/2018 - 05:27 FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
07/31/2018 - 07:59 Daiichi Sankyo Announces Split off (Simple Absorption-type Split) and Transfer of 41 Long-listed Products in Japan
07/31/2018 - 06:10 Daiichi Sankyo Announces Reversal of Tax-related Expenses in its Non-consolidated Financial Results (Japanese GAAP)
07/30/2018 - 17:03 Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
07/02/2018 - 17:04 Daiichi Sankyo Obtains Approval for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
06/14/2018 - 22:09 Daiichi Sankyo Launches FENTANYL CITRATE TAPE for 1day DAIICHI SANKYO in Japan for Long-Acting Cancer Pain Relief
05/31/2018 - 12:03 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
05/30/2018 - 12:18 Daiichi Sankyo U.S. subsidiary, Luitpold Pharmaceuticals, Inc., to Be Merged with Its Own Subsidiaries and Renamed
05/30/2018 - 11:50 Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
05/15/2018 - 17:25 Daiichi Sankyo Launches Naruvein Injection for Cancer Pain Treatment in Japan